Selecting and controlling API crystal form for pharmaceutical development--strategies and processes

Area of Science:

• Pharmaceutical Sciences
• Solid-State Chemistry
• Drug Development

Background:

• Oral dosage form development requires careful selection of the active pharmaceutical ingredient (API) form for stability and bioavailability.
• Solid-state chemistry, excipient interactions, and manufacturing processes are critical factors in API form selection.
• Understanding API solid-state properties is essential for successful drug product development.

Purpose of the Study:

• To review knowledge-based approaches for selecting crystalline API forms.
• To highlight studies aligning with the Quality by Design (QbD) framework for pharmaceutical development.
• To discuss potential API crystal form transformations during manufacturing and formulation.

Main Methods:

• Literature review of recent publications and author experiences.
• Description of concepts and approaches for knowledge-based API form selection.
• Analysis of case studies demonstrating API crystal form transformations.

Main Results:

• Outlines a systematic approach to API crystalline form selection.
• Integrates Quality by Design (QbD) principles into the selection process.
• Illustrates API form transformation risks at various development stages.

Conclusions:

• A knowledge-based approach to API form selection, guided by QbD, ensures product quality and bioavailability.
• Awareness of potential API crystal form changes is vital throughout crystallization, post-crystallization, and formulation.
• Effective API form selection is a cornerstone of successful oral dosage form development.